These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26098137)

  • 1. Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.
    Phaëton R; Gutierrez J; Jiang Z; Karabakhtsian RG; Albanese J; Sunkara J; Fisher DR; Goldberg GL; Dadachova E
    Immunotherapy; 2015; 7(6):631-40. PubMed ID: 26098137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
    Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
    Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6.
    Phaeton R; Harris M; Jiang Z; Wang XG; Einstein MH; Goldberg GL; Casadevall A; Dadachova E
    Cancer Biol Ther; 2010 Nov; 10(10):1041-7. PubMed ID: 20861673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
    Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
    Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
    Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maâlej M; Oueslati R
    J Immunoassay Immunochem; 2009; 30(1):82-96. PubMed ID: 19117204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
    PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18.
    Layman H; Rickert KW; Wilson S; Aksyuk AA; Dunty JM; Natrakul D; Swaminathan N; DelNagro CJ
    PLoS One; 2020; 15(3):e0229672. PubMed ID: 32214362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors.
    Paolini F; Amici C; Carosi M; Bonomo C; Di Bonito P; Venuti A; Accardi L
    J Exp Clin Cancer Res; 2021 Jan; 40(1):37. PubMed ID: 33485370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers.
    Reuschenbach M; Waterboer T; Wallin KL; Einenkel J; Dillner J; Hamsikova E; Eschenbach D; Zimmer H; Heilig B; Kopitz J; Pawlita M; Doeberitz Mv; Wentzensen N
    Int J Cancer; 2008 Dec; 123(11):2626-31. PubMed ID: 18785210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
    Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
    Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
    Ramos CA; Narala N; Vyas GM; Leen AM; Gerdemann U; Sturgis EM; Anderson ML; Savoldo B; Heslop HE; Brenner MK; Rooney CM
    J Immunother; 2013 Jan; 36(1):66-76. PubMed ID: 23211628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of (188)re-labeled anti-E6 C1P5 antibody in cervical cancer in mice.
    Phaeton R; Wang XG; Einstein MH; Goldberg GL; Casadevall A; Dadachova E
    Cancer; 2010 Feb; 116(4 Suppl):1067-74. PubMed ID: 20127955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
    Jiang B; Xue M
    Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.
    Hu Z; Ding W; Zhu D; Yu L; Jiang X; Wang X; Zhang C; Wang L; Ji T; Liu D; He D; Xia X; Zhu T; Wei J; Wu P; Wang C; Xi L; Gao Q; Chen G; Liu R; Li K; Li S; Wang S; Zhou J; Ma D; Wang H
    J Clin Invest; 2015 Jan; 125(1):425-36. PubMed ID: 25500889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
    Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
    Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies.
    Hu R; Dong Z; Zhang K; Pan G; Li C; Cui H
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32204370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer.
    Sharma C; Khan MA; Mohan T; Shrinet J; Latha N; Singh N
    Immunol Res; 2014 Jan; 58(1):132-8. PubMed ID: 24174302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.
    Hasan UA; Bates E; Takeshita F; Biliato A; Accardi R; Bouvard V; Mansour M; Vincent I; Gissmann L; Iftner T; Sideri M; Stubenrauch F; Tommasino M
    J Immunol; 2007 Mar; 178(5):3186-97. PubMed ID: 17312167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.